{"pub": "fox", "url": "https://foxbusiness.com/economy/generic-zantac-tabbed-in-a-voluntary-recall", "downloaded_at": "2019-09-28 01:06:52.234784+00:00", "title": "Generic Zantac tabbed in a voluntary recall amid cancer concerns", "language": "en", "text": "A popular drug to combat heartburn may be linked to cancer, causing a voluntary recall of the product.\n\nContinue Reading Below\n\nThe statement from the U.S. Food and Drug Administration (FDA) is for a voluntary recall of generic versions of Zantac, a heartburn drug that is served in tablet form. The need for the recall stems from the presence of N-nitrosodimethylamine (NDMA).\n\nThere is no current recall for \"brand-name drug Zantac,\" although the FDA is currently testing it.\n\nAccording to the World Health Organization, NDMA is listed \u201cas probably carcinogenic to humans.\u201d This has earned it a Group B2 rating from the Environmental Protection Agency, meaning that \u201cThere is inadequate evidence that it can cause cancer in humans but at present, it is far from conclusive.\u201d\n\nThe message from the FDA is clear however that \u201cConsumers taking OTC ranitidine could consider using other OTC products approved for their condition.\u201d These generic versions of ranitidine tablets are distributed at Walgreens, Walmart and Rite Aid.\n\nTicker Security Last Change %Chg WMT WALMART INC. 118.45 +0.15 +0.13% WBA WALGREENS BOOTS ALLIANCE INC. 54.41 +0.33 +0.61% RAD RITE AID 7.28 -0.55 -7.02%\n\nAdvertisement\n\nAccording to the FDA, not all ranitidine medicines are part of this recall. In addition, in their release, the FDA announced that they are \u201cnot recommending individuals stop taking all ranitidine medicines at this time.\u201d Consumers are advised to consult their health care professionals to pursue the wisest course of action.\n\nAt the present time, the FDA is continuing to test a wide range of ranitidine products. In addition, the organization has released testing methods for regulators.\n\nCLICK HERE TO READ MORE ON FOX BUSINESS", "description": "Generic versions of Zantac are part of a voluntary recall due to concerns over a carcinogen that is linked to cancer.", "authors": ["Kristian Dyer"], "top_image": "https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2019/09/0/0/zantac-iStock.jpg?ve=1&tl=1", "published_at": "2019-09-27"}